Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (251-260 of 580) with videos related to

Pageof 58
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersDirk Schadendorf, Caroline Robert, Reinhard Dummer, et al.
Biomolecules|February 12, 2021
Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 SignalingAkshita B Bhatt, Saloni Patel, Margarite D Matossian, et al.
Human Pathology|December 17, 2009
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysJanice M Mehnert, Mary M McCarthy, Lucia Jilaveanu, et al.
The Journal of Investigative Dermatology|December 17, 2008
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomideTobias Sinnberg, Konstantinos Lasithiotakis, Heike Niessner, et al.
Journal of Neuro-Oncology|April 13, 2015
Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor eraDaniel A Wattson, Ryan J Sullivan, Andrzej Niemierko, et al.
British Journal of Cancer|January 25, 2007
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levelsK S M Smalley, R Contractor, N K Haass, et al.
JAMA Oncology|March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized TrialNaomi B Haas, Judith Manola, Janice P Dutcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanomaKeith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
The Journal of Investigative Dermatology|February 9, 2016
Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma SurvivalMi Ryung Roh, Sameer Gupta, Kyu-Hyun Park, et al.
Journal of the American College of Cardiology|August 1, 1985
Results of a randomized prospective trial of intraaortic balloon counterpulsation and intravenous nitroglycerin in patients with acute myocardial infarctionJ T Flaherty, L C Becker, J L Weiss, et al.
Pageof 58

Showing results (251-260 of 580) with videos related to

Sort By:
Pageof 58
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersDirk Schadendorf, Caroline Robert, Reinhard Dummer, et al.
Biomolecules|February 12, 2021
Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 SignalingAkshita B Bhatt, Saloni Patel, Margarite D Matossian, et al.
Human Pathology|December 17, 2009
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysJanice M Mehnert, Mary M McCarthy, Lucia Jilaveanu, et al.
The Journal of Investigative Dermatology|December 17, 2008
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomideTobias Sinnberg, Konstantinos Lasithiotakis, Heike Niessner, et al.
Journal of Neuro-Oncology|April 13, 2015
Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor eraDaniel A Wattson, Ryan J Sullivan, Andrzej Niemierko, et al.
British Journal of Cancer|January 25, 2007
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levelsK S M Smalley, R Contractor, N K Haass, et al.
JAMA Oncology|March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized TrialNaomi B Haas, Judith Manola, Janice P Dutcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanomaKeith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
The Journal of Investigative Dermatology|February 9, 2016
Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma SurvivalMi Ryung Roh, Sameer Gupta, Kyu-Hyun Park, et al.
Journal of the American College of Cardiology|August 1, 1985
Results of a randomized prospective trial of intraaortic balloon counterpulsation and intravenous nitroglycerin in patients with acute myocardial infarctionJ T Flaherty, L C Becker, J L Weiss, et al.
Pageof 58